Cargando…

The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients

With the outbreak of a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the public healthcare systems are facing great challenges. Coronavirus disease 2019 (COVID‐19) could develop into severe pneumonia, acute respiratory distress syndrome and multi‐organ failure. Remar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Hengzhi, Wang, Dao Wen, Chen, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521316/ https://www.ncbi.nlm.nih.gov/pubmed/32713161 http://dx.doi.org/10.1111/jcmm.15674

Ejemplares similares

DPP4 as a Potential Candidate in Cardiovascular Disease
por: Chen, Si-Yu, et al.
Publicado: (2022)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
por: Nag, Snehasish, et al.
Publicado: (2023)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

DPP4 Inhibitors and COVID-19–Holy Grail or Another Dead End?
por: Krejner-Bienias, Alicja, et al.
Publicado: (2021)

Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
por: Sharma, Ashwani, et al.
Publicado: (2022)

Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms
por: Zakaria, Esraa M., et al.
Publicado: (2022)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

DPP-4 inhibitors and severe course of illness in patients with COVID-19
por: Bouhanick, Béatrice, et al.
Publicado: (2021)

Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria
por: Haluzík, Martin, et al.
Publicado: (2013)

DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
por: Dicker, Dror
Publicado: (2011)

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
por: Sebastián-Martín, Alba, et al.
Publicado: (2022)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
por: Lin, Yi-Hsuan, et al.
Publicado: (2018)

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
por: Bonora, B. M., et al.
Publicado: (2021)

Reply to letter to the editor regarding “Use of DPP-4 inhibitors in patients with COVID-19”
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020)

DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
por: Valencia, Inés, et al.
Publicado: (2020)

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
por: Rhee, Sang Youl, et al.
Publicado: (2021)

Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
por: Kang, Seon Mee, et al.
Publicado: (2021)

Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors
por: Del Prato, Stefano, et al.
Publicado: (2017)

The Role of DPP4 Activity in Cardiovascular Districts: In Vivo and In Vitro Evidence
por: Pala, L., et al.
Publicado: (2013)

Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
por: Schuetz, Charles Andy, et al.
Publicado: (2015)

Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI
por: Xue, Jujun, et al.
Publicado: (2020)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

Liraglutide relieves cardiac dilated function than DPP‐4 inhibitors
por: Hiramatsu, Takeyuki, et al.
Publicado: (2018)

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
por: Mikhail, Nasser
Publicado: (2008)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
por: Scheen, André J.
Publicado: (2021)

The role of miR-320 in glucose and lipid metabolism disorder-associated diseases
por: Du, Hengzhi, et al.
Publicado: (2021)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
por: Foley, James E, et al.
Publicado: (2010)

Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents
por: Mathur, Vishal, et al.
Publicado: (2023)

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020)

Acute myocardial infarction associated to DPP-4 inhibitors
por: Nunes, J P L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fuo31gvm7daaurdvef7ha5tsm6